Toray Industries ((TRYIY)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Toray Industries is currently conducting a Phase 2 clinical study titled A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer. The study aims to evaluate the efficacy, safety, and optimal dosing of TRK-950 in combination with ramucirumab and paclitaxel, compared to the standard treatment of ramucirumab and paclitaxel alone, in patients with gastric or gastro-esophageal junction adenocarcinoma.
The study is testing two experimental interventions: TRK-950 at doses of 5 mg/kg and 10 mg/kg, both in combination with ramucirumab and paclitaxel. These treatments are administered intravenously in a 28-day cycle, aiming to improve outcomes for patients with gastric cancer.
This interventional study employs a randomized, parallel assignment model with no masking, focusing primarily on treatment efficacy. The study’s primary purpose is to determine the best treatment approach for gastric cancer patients.
The study began on August 29, 2023, with an estimated primary completion date in 2025. The latest update was submitted on July 30, 2025, indicating ongoing progress in the trial.
This study could significantly impact Toray Industries’ stock performance, as successful results may enhance the company’s position in the oncology market. Investors should watch for updates, as positive outcomes could influence market dynamics and investor sentiment within the pharmaceutical sector.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.